RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

Benzinga Newsdesk www.benzinga.com Positive 92.3%

Neg 0% Neu 0% Pos 92.3%

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $34 to $35.